Novo Nordisk's obesity drug Wegovy leads to greater weight loss in women than men

From Investing.com: 2024-06-23 16:36:32

Novo Nordisk’s obesity drug Wegovy was found to help women with heart failure with preserved ejection fraction lose more weight than men with the same condition in trials with 1,145 patients. The drug produced similar improvements in symptoms, physical limitations, and exercise function regardless of sex, with fewer adverse events reported in patients who took Wegovy.

Data from trials presented at the American Diabetes Association’s scientific meeting showed a 2.4 mg dose of semaglutide reduced body weight more in females compared to males. While both groups saw similar improvements in heart failure symptoms, female patients lost an average of 9.6% of their weight while males lost about 7.2%.

Half of the patients in Novo’s trials were female, with higher BMI and worse heart failure symptoms. Both males and females improved by roughly 7.5 points on a 0-100 point scale in heart failure benefits. Studies have shown a greater weight-loss response in women than men with semaglutide, but more research is needed to understand why this is the case.



Read more at Investing.com: Novo’s Wegovy induces higher weight loss in women than men with same heart condition, study shows By Reuters